Irene Ghobrial, MD
The combination of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone has excellent activity and is well-tolerated in the treatment of high-risk smoldering multiple myeloma (SMM), providing hope that it can delay or even halt progression to MM. Results of a phase II trial of this combination revealed an overall response rate (ORR) in excess of 80% in high-risk SMM on the basis of newly defined criteria,1
said Irene Ghobrial, MD, who presented the data at the 2016 ASH Annual Meeting.
Early data indicate PFS may be better than lenalidomide/dexamethasone, but “we need long-term follow-up to determine PFS as well as whether those patients indeed would have delayed end-organ and delayed myeloma events,” said Ghobrial. “We’re looking now at immune profiling and mechanisms of response to see, indeed, who are those patients who have a deep response, and whether that correlates with certain immune profiling in those patients.”
- Ghobrial IM, Badros AZ, Vredenburgh JJ, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Presented at: American Society of Hematology 58th Annual Meeting; December 3-6, 2016; San Diego, CA. Abstract 976.
- Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438-447.
... to read the full story